Table 5. Characteristics of included studies from other Asian countries and regions.
Country/region | ## | Author | Year | Institution | City | Study cohort | Tissue type | Technique | Total PTC | BRAF+ | BRAF rate (%) |
---|---|---|---|---|---|---|---|---|---|---|---|
Saudi Arabia | 1 | Abubaker J (129) | 2008 | King Faisal Specialist Hospital | Riyadh | 1988–2004 | FFPE | Seq | 296 | 153 | 52 |
2 | Schulten HJ (130) | 2012 | King Abdulaziz University + King Faisal Specialist Hospital | Jeddah | 1995–2011 | FFPE | PCR, Seq | 213 | 87 | 41 | |
3 | Zou M (131) | 2014 | King Faisal Specialist Hospital | Riyadh | 1987–2006 | Fresh frozen | Seq | 88 | 42 | 48 | |
4 | Qasem E (132) | 2015 | King Faisal Specialist Hospital | Riyadh | 2008–2011 | FFPE | Seq | 243 | 105 | 43 | |
5 | Murugan AK (133) | 2016 | King Faisal Specialist Hospital | Riyadh | n/s | FFPE | Seq | 201 | 95 | 47 | |
6 | Alzahrani AS (20) | 2017 | King Faisal Specialist Hospital | Riyadh | 1998–2015 | FFPE | Seq | 79 | 19 | 24 | |
Iran | 1 | Mohammadi-Asl J (134) | 2009 | Tehran University of Medical Science | Tehran | 2007–2008 | FFPE | PCR-RFLP | 28 | 20 | 71 |
2 | Ranjbari N (135) | 2013 | Imam Khomeini Hospital | Ahvaz | 2000–2010 | FFPE | PCR-RFLP | 63 | 49 | 78 | |
3 | Daliri M (136) | 2014 | Ghaem Hospital | Mashhad | 1999–2014 | FFPE | PCR-RFLP | 69 | 28 | 41 | |
4 | Zarkesh M (137) | 2018 | Erfan Hopital + Atiyeh Hospital | Tehran | 2015–2016 | Fresh frozen | Seq | 60 | 24 | 40 | |
5 | Ghasemi M (138) | 2019 | Khalili Hospital | Shiraz | 2012–2017 | FFPE | PCR-RFLP | 79 | 65 | 82 | |
Iraq | 1 | Salih A (139) | 2017 | Duhok Private Medical Laboratory + Vin Private Medical laboratory | Duhok | 2011–2015 | FFPE | qPCR | 47 | 12 | 26 |
Kazakhstan | 1 | Kumagai A (22) | 2007 | Medical Institute of Semipalatinsk | Semipalatinsk | 2004–2006 | FNA | PCR-RFLP | 76 | 19 | 25 |
2 | Tlegenov AS (140) | 2018 | Kazakh Scientific Research Institute of Oncology and Radiology | Almaty | 2016–2017 | Fresh frozen | IHC | 92 | 62 | 67 | |
Myanmar | 1 | Than MM (141) | 2017 | Yangon University of Medicine | Yangon | 2014–2016 | FFPE | PCR | 44 | 10 | 23 |
Thailand | 1 | Choden S (142) | 2020 | Chulalongkorn University | Bangkok | 2007–2017 | FFPE | IHC | 476 | 290 | 61 |
Vietnam | 1 | Vuong HG (27) | 2016 | Cho Ray Hospital | Ho Chi Minh | 2011–2014 | FFPE | AS-PCR | 53 | 44 | 83 |
Indonesia | 1 | Brahma B (143) | 2013 | Mangunkusumo Hospital Medical Faculty University | Jakarta | 2010–2011 | FNA | PCR RFLP | 44 | 17 | 39 |
2 | Kristiani E (144) | 2016 | Siloam Hospitals Lippo Village | Tangerang | n/s | FFPE | IHC | 50 | 17 | 34 | |
Singapore | 1 | Yang P (145) | 2015 | Singapore National University Hospital | Singapore | n/s | FFPE | IHC | 49 | 39 | 80 |
2 | Goh X (146) | 2019 | Singapore National University Hospital | Singapore | 2010–2012 | FFPE | Seq | 75 | 42 | 56 | |
Taiwan | 1 | Liu RT (147) | 2005 | Chang Gung Memorial Hospital | Kaohsiung | 1997–2002 | FFPE | Seq | 105 | 49 | 47 |
2 | Chang YS (148) | 2013 | China Medical University Hospital | Taichung | n/s | Fresh frozen | Seq | 52 | 32 | 62 | |
Hong Kong | 1 | Lo CC (149) | 2004 | University of Hong Kong | Hong Kong | 2001–2003 | FFPE | Seq | 34 | 17 | 50 |
2 | Law Y (150) | 2009 | The Hong Kong Polytechnic University | Hong Kong | n/s | FFPE | PCR RFLP | 50 | 24 | 48 | |
Philippines | 1 | Navarro-Locsin CG (151) | 2016 | St. Luke’s Medical Center | Quezon City | 2010–2012 | FFPE | Seq + qPCR | 65 | 25 | 38 |
2 | Espiritu GAM (152) | 2019 | Makati Medical Center | Makati | 2016 | FFPE | Seq | 17 | 12 | 71 |
AS-PCR, allele specific-polymerase chain reaction; FFPE, formalin fixed paraffin embedded tissues; FNA, fine needle aspiration; IHC, immunohistochemistry; n/s, not specified; PCR-RFLP, polymerase chain reaction-restriction fragment length polymorphism; qPCR, quantitative polymerase chain reaction; Seq, sequencing